Abstract: FR-PO1137
Long-Term Kidney Function of Hospitalized COVID-19 Survivors Who Did or Did Not Develop AKI
Session Information
- COVID-19 - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Romero, Nancy, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Becerra-Gutiérrez, César A., Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Villasana B, Mariana C., Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Martin del Campo, Fabiola, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Rojas-Campos, Enrique, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
- Cueto-Manzano, Alfonso M., Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
Group or Team Name
- UIMER.
Background
COVID-19 increases acute kidney injury (AKI) risk; however, it is unclear its long-term effect in high CKD prevalence settings. Aim: To assess evolution, at least 6 months after discharge, of kidney function in hospitalized COVID-19 survivors who did or did not develop AKI.
Methods
Prospective cohort of confirmed COVID-19 patients (03/20-10/21). From inpatient registry, survivors were contacted; those who agreed to participate had a clinical interview and eGFR and albumin/creatinine ratio evaluation.
Results
Of 585 COVID-19 patients discharged alive, 121 (21%) developed AKI; 166 without AKI and 34 with AKI were included and evaluations performed at 20.0±0.3 months. Comparisons between groups are shown in Table 1 and Table 2. Overall mean time survival was 26.1±0.5 months; comparison according to AKI development is shown in Figure.
Conclusion
A fifth of surviving patients hospitalized for COVID-19 developed AKI, 73% of them recovered kidney function upon discharge. Patients with AKI had lower kidney function throughout the study and higher ACR at end of follow-up compared to those without AKI; however, the latter displayed slight eGFR decrease at the end of the study compared to baseline. Survival was significantly lower in patients with AKI and seemed to be worse in those with higher stages.
Table 2. Comparison of kidney function recovery and treatment according to KDIGO classification
| Variable | AKI 1 (n 15) | AKI 2 (n 13) | AKI 3 (n 6) | p |
| Kidney function recovery, n (%) Treatment, n (%) Conservative Hemodialysis Peritoneal dialysis | 10 (67) 14 (93) 1 (7) 0 | 11 (85) 12 (92) 1 (8) 0 | 4 (67) 4 (67) 1 (17) 1 (17) | 0.51 0.23 |